Cagrilintide

Investigated uses

• Obesity and weight management, alone and with semaglutide.

Mechanism and hypotheses

• Cagrilintide is a long-acting amylin analogue that engages amylin/calcitonin-family receptors and reduces energy intake in clinical development.
• Hypothesized: The precise contribution of individual receptor subtypes to long-term weight reduction remains under investigation.

Human evidence

• A phase 2 trial randomized 706 adults to weekly cagrilintide dose arms, daily liraglutide or placebo for 26 weeks; weight loss was dose-dependent and exceeded placebo. Limitations: Short duration for chronic therapy; investigational product and sponsor setting.

Safety highlights

• Gastrointestinal adverse events, especially nausea, were common in phase 2.
• Long-term pancreatic, biliary, cardiovascular and rare-event risks remain incompletely characterized.

Regulatory context

Cagrilintide was not FDA-approved as of the review date; FDA states it cannot be used in compounding under the cited framework.